Cutting Edge Science – Personalised medicine in Parkinson’s: From theory to reality

In July this year, the Parkinson’s Academy presented “Cutting Edge Science for Parkinson’s Clinicians”, an educational meeting sponsored by Bial Pharma UK Ltd. This one-day meeting was chaired by Dr Peter Fletcher and attended by a diverse audience of neurologists, care of the elderly physicians, psychiatrists and Parkinson’s nurses. The meeting was a chance to […]

Continue Reading »

Cutting Edge Science – Where are we going with medications?

In July this year, the Parkinson’s Academy presented “Cutting Edge Science for Parkinson’s Clinicians”, an educational meeting sponsored by Bial Pharma UK Ltd. This one-day meeting was chaired by Dr Peter Fletcher and attended by a diverse audience of neurologists, care of the elderly physicians, psychiatrists and Parkinson’s nurses. The meeting was a chance to […]

Continue Reading »

Cutting Edge Science – Do we need to rethink imaging?

In July this year, the Parkinson’s Academy presented “Cutting Edge Science for Parkinson’s Clinicians”, an educational meeting sponsored by Bial Pharma UK Ltd. This one-day meeting was chaired by Dr Peter Fletcher and attended by a diverse audience of neurologists, care of the elderly physicians, psychiatrists and Parkinson’s nurses. The meeting was a chance to […]

Continue Reading »

Updated guidance on Occupational Therapy in Parkinson’s released

6 November, 2018 | Posted in: ,

The Royal College of Occupational Therapists have released new guidance on the use of occupational therapy in managing Parkinson’s. Currently holding the motto ‘helping people to live, not exist’, the College are, as with many elements of service and care within the NHS, having to make a strong, evidence-based case for their work. This guidance, […]

Continue Reading »

Cutting Edge Science – Do we need to rethink genetic testing?

In July this year, the Parkinson’s Academy presented “Cutting Edge Science for Parkinson’s Clinicians”, an educational meeting sponsored by Bial Pharma UK Ltd. This one-day meeting was chaired by Dr Peter Fletcher and attended by a diverse audience of neurologists, care of the elderly physicians, psychiatrists and Parkinson’s nurses. The meeting was a chance to […]

Continue Reading »

Next step in personalised medicine to revolutionise Parkinson’s care

23 October, 2018 | Posted in:

Ray Chaudhuri, Professor in movement disorders and neurology at King’s College Hospital (KCH), has produced his latest piece of research in Parkinson’s care and management – the development of a personalised medicines checklist. The Director of the National Parkinson’s Foundation Centre of Excellence at King’s Health Partners (comprising King’s College London and KCH) has been […]

Continue Reading »

Research Engagement: A meeting dedicated to Research Engagement and Involvement

20 September, 2018 | Posted in:

Our Parkinson’s Academy has a 16 year pedigree of designing, delivering and evaluating its MasterClasses in order to educate UK frontline clinicians, support quality improvement and provide a forum for the Parkinson’s (PD) clinical family to network. We are very proud that those clinicians reflect real-world practice in that they are drawn from medicine, nursing […]

Continue Reading »

This week’s Star Showcase: the Founding Four

14 September, 2018 | Posted in:

This week’s Star is not one but four people: our Founders Peter Fletcher, Doug MacMahon, David Stewart and Sue Thomas. Their initial idea was to develop a new kind of educational model which would both upskill and support clinicians in their clinical knowledge of Parkinson’s but also see practical changes in service quality and delivery. […]

Continue Reading »

Medication alert: Sinemet supply issue September 2018

10 September, 2018 | Posted in:

Article originally published on 6 September 2018 by Parkinson’s UK here   Parkinson’s UK has reported that it has been made aware by Merck Sharp & Dohme Limited (MSD) that there is currently a supply issue with some of their Sinemet products in the UK and other countries. Current manufacturing capacity constraints mean that the […]

Continue Reading »